Biopharmx (BPMX) Trading Up -10.5%
Biopharmx Corp (NYSEAMERICAN:BPMX) shares were up 10.5% on Monday . The company traded as high as $0.19 and last traded at $0.17. Approximately 4,767,908 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 11,409,313 shares. The stock had previously closed at $0.19.
Separately, Maxim Group reaffirmed a “buy” rating and issued a $1.50 price target on shares of Biopharmx in a research report on Friday, December 8th.
The firm has a market cap of $21.46, a price-to-earnings ratio of -0.62 and a beta of 1.40.
In other Biopharmx news, Director Stephen Morlock acquired 330,000 shares of Biopharmx stock in a transaction on Friday, November 24th. The shares were bought at an average price of $0.15 per share, with a total value of $49,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.